Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175100 | 0.79 | MEN1 (0.39) | AKT1PTGDR2NR1H4CNR1ALDH1A1 | |
| SCHEMBL10175162 | 0.75 | USP2 (0.43) | CNR1ALDH1A1 | |
| SCHEMBL10175160 | 0.75 | USP2 (0.43) | CNR1ALDH1A1 | |
| SCHEMBL28169156 | 0.68 | ALDH1A1 (0.44) | BCHEACHEALDH1A1 | |
| SCHEMBL7650508 | 0.67 | CYP1A2 (0.46) | PTGS2PTGS1CNR1ALDH1A1SLC6A2 | |
| SCHEMBL60105 | 0.66 | ALDH1A1 (0.43) | BCHEACHEALDH1A1SLC6A2SLC6A4 | |
| SCHEMBL553741 | 0.66 | CHRM1 (0.50) | SLC6A2SLC6A4SLC6A3MAPTCYP1A2 | |
| SCHEMBL553920 | 0.66 | CHRM1 (0.50) | SLC6A2SLC6A4SLC6A3MAPTCYP1A2 | |
| SCHEMBL31264458 | 0.66 | CHRM1 (0.50) | SLC6A2SLC6A4SLC6A3MAPTCYP1A2 | |
| SCHEMBL31451120 | 0.66 | CHRM1 (0.50) | SLC6A2SLC6A4SLC6A3MAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | AKT1 313/4885PTGDR2 315/4885NR1H4 2565/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | AKT1 313/4885PTGDR2 315/4885NR1H4 2565/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | AKT1 1409/4885PTGDR2 1720/4885NR1H4 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.